Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 2;25(1):91-97.
doi: 10.18295/squmj.10.2024.057. eCollection 2025.

Empagliflozin Use in Cardiac Transplant Patients: Real-world experience from Saudi Arabia

Muhammad I Butt  1   2 , Roaa M H Albalwi  1 , Norah Alnassar  3 , Reem Alghamdi  3
Affiliations

Empagliflozin Use in Cardiac Transplant Patients: Real-world experience from Saudi Arabia

Muhammad I Butt et al. Sultan Qaboos Univ Med J. .

Abstract

Objectives: Sodium-glucose transport protein 2 (SGLT2) inhibitors are used in the treatment of patients with type 2 diabetes. Besides their beneficial metabolic effects, such as lowering glycated haemoglobin, body weight and blood pressure, these agents have shown favourable and protective effects on both the heart and kidneys. Notably, these cardio-renal benefits are even seen in individuals without diabetes. However, there is limited evidence regarding the safety and efficacy of SGLT2 inhibitors in cardiac transplant recipients. This study aimed to assess the safety and efficacy of empagliflozin in cardiac transplant recipients with diabetes.

Methods: This retrospective study was conducted at the King Faisal Specialist Hospital & Research Centre in Riyadh, Saudi Arabia, from June 2003 to May 2024. Patients from the cardiac transplant recipient register who were taking empagliflozin or a combination of empagliflozin and metformin were included. Consequently, their safety and efficacy parameters were examined.

Results: A total of 20 patients were included in this study. There was an improvement in haemoglobin A1C (HbA1C) levels, body weight and stability in serum creatinine. Additionally, there was no increased risk of genitourinary infections, hypoglycaemia or diabetic ketoacidosis.

Conclusions: Although larger studies are needed to examine the use of empagliflozin in cardiac transplant patients, this small study provides assurance that empagliflozin is safe for use in cardiac transplant recipients.

Keywords: Empagliflozin; SGLT2 Inhibitors; Saudi Arabia; Type 2 Diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Fig. 1.
Fig. 1.
Change in glycated haemoglobin in patients from the current study HbA1c = glycated haemoglobin; SD = standard deviation; IQR = interquartile range. *Missing information in 2 patients.
Fig. 2.
Fig. 2.
Change in body weight in patients from the current study. SD = standard deviation; IQR = interquartile range. *Missing information in 1 patient.
Fig. 3.
Fig. 3.
Change in the body mass index in patients from the current study. BMI = body mass index; SD = standard deviation; IQR = interquartile range. *Missing information in 1 patient.
Fig. 4.
Fig. 4.
Change in serum creatinine in patients from the current study. SD = standard deviation; IQR = interquartile range.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A review. Front Med (Lausanne) 2021; 8:777861. https://doi.org/10.3389/fmed.2021.777861. 10.3389/fmed.2021.777861 - DOI - DOI - PMC - PubMed
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–28. https://doi.org/10.1056/NEJMoa1504720. 10.1056/NEJMoa1504720 - DOI - DOI - PubMed
    1. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413–24. https://doi.org/10.1056/NEJMoa2022190. 10.1056/NEJMoa2022190 - DOI - DOI - PubMed
    1. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385:1451–61. https://doi.org/10.1056/NEJMoa2107038. 10.1056/NEJMoa2107038 - DOI - DOI - PubMed
    1. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol 2021; 6:148–58. https://doi.org/10.1001/jamacardio.2020.4511. 10.1001/jamacardio.2020.4511 - DOI - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources